Basics Aclaris Therapeutics, Inc. Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. IPO Date: October 7, 2015 Sector: Healthcare Industry: Biotech Market Cap: $149.43M Activated in VL: True Average Daily Range Avg Daily Range: $0.35 | 3.17% Avg Daily Range (30 D): $0.05 | 3.65% Avg Daily Range (90 D): $0.06 | 3.05% Institutional Daily Volume Avg Daily Volume: .67M Avg Daily Volume (30 D): .71M Avg Daily Volume (90 D): .75M Trade Size Avg Trade Size (Sh.): 156 Avg Trade Size (Sh.) (30 D): 172 Avg Trade Size (Sh.) (90 D): 155 Institutional Trades Total Inst.Trades: 1,171 Avg Inst. Trade: $1.56M Avg Inst. Trade (30 D): $2.52M Avg Inst. Trade (90 D): $1.03M Avg Inst. Trade Volume: .13M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.48M Avg Closing Trade (30 D): $2.52M Avg Closing Trade (90 D): $2.52M Avg Closing Volume: 127.61K         News May 9, 2025 @ 11:00 AM Aclaris Therapeutics to Participate in the HC Wain... Source: N/A Apr 29, 2025 @ 11:00 AM Aclaris Therapeutics Appoints Jesse Hall, M.D. as ... Source: N/A Mar 3, 2025 @ 6:00 PM JAK Inhibitors Clinical Trial Pipeline Appears Rob... Source: Delveinsight Sep 10, 2024 @ 11:00 AM Aclaris Therapeutics to Participate in the 2024 Ca... Source: N/A Jul 23, 2024 @ 11:31 AM Aclaris Therapeutics And 3 Other Stocks Under $2 I... Source: Avi Kapoor Financials   TTM Q4 2024 FY 2024 Basic EPS $-1.71 $-1.21 $-1.71 Diluted EPS $-1.71 $-1.21 $-1.71 Revenue $ 18.72M $ 9.21M $ 18.72M Gross Profit $ 15.93M $ 8.51M $ 15.93M Net Income / Loss $ -132.07M $ -96.55M $ -132.07M Operating Income / Loss $ -141.93M $ -99.68M $ -141.93M Cost of Revenue $ 2.79M $ .71M $ 2.79M Net Cash Flow $ -15.31M $ -23.08M $ -15.31M PE Ratio